Skip to main content
NCBI home page
Journal of the National Medical Association logoLink to Journal of the National Medical Association
. 1994 Oct;86(10):765–774.

Common emergencies in cancer medicine: infectious and treatment-related syndromes, Part I.

C R Thomas Jr 1, L V Wood 1, J G Douglas 1, K J Stelzer 1, W Koh 1, R Panicker 1
PMCID: PMC2607708  PMID: 7807561

Abstract

This two-part article, the last in a series of articles on cancer emergencies, summarizes the common medical emergencies that can occur as a result of infectious processes (Part I) and antitumor treatment secondary to chemotherapy, biological response modifiers, or radiotherapy (Part II). The use of high-dose cytotoxic agents, coupled with the common instillation of indwelling central venous access devices, have altered the spectrum of infectious etiologies that are appreciated in clinical practice. In addition, a myriad of cytotoxic agents and radiotherapeutic treatment schemes are used widely in clinical oncologic practice. While most of their related side effects are not considered life-threatening emergencies, they can be fatal if not recognized early and treated promptly. Moreover, some of these infectious and treatment-related sequelae can be prevented.

Full text

PDF
765

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Antman K. S., Griffin J. D., Elias A., Socinski M. A., Ryan L., Cannistra S. A., Oette D., Whitley M., Frei E., 3rd, Schnipper L. E. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression. N Engl J Med. 1988 Sep 8;319(10):593–598. doi: 10.1056/NEJM198809083191001. [DOI] [PubMed] [Google Scholar]
  2. Benezra D., Kiehn T. E., Gold J. W., Brown A. E., Turnbull A. D., Armstrong D. Prospective study of infections in indwelling central venous catheters using quantitative blood cultures. Am J Med. 1988 Oct;85(4):495–498. doi: 10.1016/s0002-9343(88)80084-6. [DOI] [PubMed] [Google Scholar]
  3. Clarke D. E., Raffin T. A. Infectious complications of indwelling long-term central venous catheters. Chest. 1990 Apr;97(4):966–972. doi: 10.1378/chest.97.4.966. [DOI] [PubMed] [Google Scholar]
  4. Clift R. A., Buckner C. D. Symposium on infectious complications of neoplastic disease (Part II). Granulocyte transfusions. Am J Med. 1984 Apr;76(4):631–636. doi: 10.1016/0002-9343(84)90287-0. [DOI] [PubMed] [Google Scholar]
  5. Crawford J., Ozer H., Stoller R., Johnson D., Lyman G., Tabbara I., Kris M., Grous J., Picozzi V., Rausch G. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med. 1991 Jul 18;325(3):164–170. doi: 10.1056/NEJM199107183250305. [DOI] [PubMed] [Google Scholar]
  6. De Pauw B. E., Deresinski S. C., Feld R., Lane-Allman E. F., Donnelly J. P. Ceftazidime compared with piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer. A multicenter randomized trial. The Intercontinental Antimicrobial Study Group. Ann Intern Med. 1994 May 15;120(10):834–844. doi: 10.7326/0003-4819-120-10-199405150-00004. [DOI] [PubMed] [Google Scholar]
  7. Feld R. The compromised host. Eur J Cancer Clin Oncol. 1989;25 (Suppl 2):S1–S7. [PubMed] [Google Scholar]
  8. Harris R. L., Musher D. M., Bloom K., Gathe J., Rice L., Sugarman B., Williams T. W., Jr, Young E. J. Manifestations of sepsis. Arch Intern Med. 1987 Nov;147(11):1895–1906. [PubMed] [Google Scholar]
  9. Hathorn J. W. Empirical antibiotics for febrile neutropenic cancer patients. Eur J Cancer Clin Oncol. 1989;25 (Suppl 2):S43–S51. [PubMed] [Google Scholar]
  10. Hibberd P. L., Rubin R. H. Approach to immunization in the immunosuppressed host. Infect Dis Clin North Am. 1990 Mar;4(1):123–142. [PubMed] [Google Scholar]
  11. Jehn U. Managing fungal and viral infection in the immunocompromised host. Recent Results Cancer Res. 1988;108:61–70. doi: 10.1007/978-3-642-82932-1_9. [DOI] [PubMed] [Google Scholar]
  12. Kahn R. C. Shock as a complication of cancer. Crit Care Clin. 1988 Jan;4(1):129–145. [PubMed] [Google Scholar]
  13. Klastersky J. Empirical antimicrobial therapy for febrile granulocytopenic cancer patients: lessons from four EORTC trials. Recent Results Cancer Res. 1988;108:53–60. doi: 10.1007/978-3-642-82932-1_8. [DOI] [PubMed] [Google Scholar]
  14. Klastersky J., Zinner S. H., Calandra T., Gaya H., Glauser M. P., Meunier F., Rossi M., Schimpff S. C., Tattersall M., Viscoli C. Empiric antimicrobial therapy for febrile granulocytopenic cancer patients: lessons from four EORTC trials. Eur J Cancer Clin Oncol. 1988;24 (Suppl 1):S35–S45. [PubMed] [Google Scholar]
  15. Lopez-Berestein G., Bodey G. P., Fainstein V., Keating M., Frankel L. S., Zeluff B., Gentry L., Mehta K. Treatment of systemic fungal infections with liposomal amphotericin B. Arch Intern Med. 1989 Nov;149(11):2533–2536. [PubMed] [Google Scholar]
  16. Meyers J. D., Reed E. C., Shepp D. H., Thornquist M., Dandliker P. S., Vicary C. A., Flournoy N., Kirk L. E., Kersey J. H., Thomas E. D. Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation. N Engl J Med. 1988 Jan 14;318(2):70–75. doi: 10.1056/NEJM198801143180202. [DOI] [PubMed] [Google Scholar]
  17. Mitchell C. D. Management of infections in the neutropenic child with cancer. Pediatr Ann. 1988 Nov;17(11):677-8, 680-6. [PubMed] [Google Scholar]
  18. Morell A., Barandun S. Prophylactic and therapeutic use of immunoglobulin for intravenous administration in patients with secondary immunodeficiencies associated with malignancies. Pediatr Infect Dis J. 1988 May;7(5 Suppl):S87–S91. [PubMed] [Google Scholar]
  19. Mueller B. U., Skelton J., Callender D. P., Marshall D., Gress J., Longo D., Norton J., Rubin M., Venzon D., Pizzo P. A. A prospective randomized trial comparing the infectious and noninfectious complications of an externalized catheter versus a subcutaneously implanted device in cancer patients. J Clin Oncol. 1992 Dec;10(12):1943–1948. doi: 10.1200/JCO.1992.10.12.1943. [DOI] [PubMed] [Google Scholar]
  20. Nemunaitis J., Rabinowe S. N., Singer J. W., Bierman P. J., Vose J. M., Freedman A. S., Onetto N., Gillis S., Oette D., Gold M. Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. N Engl J Med. 1991 Jun 20;324(25):1773–1778. doi: 10.1056/NEJM199106203242504. [DOI] [PubMed] [Google Scholar]
  21. Neumanaitis J. Granulocyte-macrophage-colony-stimulating factor: a review from preclinical development to clinical application. Transfusion. 1993 Jan;33(1):70–83. doi: 10.1046/j.1537-2995.1993.33193142315.x. [DOI] [PubMed] [Google Scholar]
  22. Nichols C. R., Fox E. P., Roth B. J., Williams S. D., Loehrer P. J., Einhorn L. H. Incidence of neutropenic fever in patients treated with standard-dose combination chemotherapy for small-cell lung cancer and the cost impact of treatment with granulocyte colony-stimulating factor. J Clin Oncol. 1994 Jun;12(6):1245–1250. doi: 10.1200/JCO.1994.12.6.1245. [DOI] [PubMed] [Google Scholar]
  23. Pizzo P. A. Considerations for the prevention of infectious complications in patients with cancer. Rev Infect Dis. 1989 Nov-Dec;11 (Suppl 7):S1551–S1563. doi: 10.1093/clinids/11.supplement_7.s1551. [DOI] [PubMed] [Google Scholar]
  24. Pizzo P. A., Hathorn J. W., Hiemenz J., Browne M., Commers J., Cotton D., Gress J., Longo D., Marshall D., McKnight J. A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med. 1986 Aug 28;315(9):552–558. doi: 10.1056/NEJM198608283150905. [DOI] [PubMed] [Google Scholar]
  25. Pizzo P. A. Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med. 1993 May 6;328(18):1323–1332. doi: 10.1056/NEJM199305063281808. [DOI] [PubMed] [Google Scholar]
  26. Pizzo P. A., Robichaud K. J., Gill F. A., Witebsky F. G. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med. 1982 Jan;72(1):101–111. doi: 10.1016/0002-9343(82)90594-0. [DOI] [PubMed] [Google Scholar]
  27. Riddell S. R., Watanabe K. S., Goodrich J. M., Li C. R., Agha M. E., Greenberg P. D. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science. 1992 Jul 10;257(5067):238–241. doi: 10.1126/science.1352912. [DOI] [PubMed] [Google Scholar]
  28. Roilides E., Pizzo P. A. Modulation of host defenses by cytokines: evolving adjuncts in prevention and treatment of serious infections in immunocompromised hosts. Clin Infect Dis. 1992 Sep;15(3):508–524. doi: 10.1093/clind/15.3.508. [DOI] [PubMed] [Google Scholar]
  29. Roilides E., Walsh T. J., Pizzo P. A., Rubin M. Granulocyte colony-stimulating factor enhances the phagocytic and bactericidal activity of normal and defective human neutrophils. J Infect Dis. 1991 Mar;163(3):579–583. doi: 10.1093/infdis/163.3.579. [DOI] [PubMed] [Google Scholar]
  30. Rubin M., Hathorn J. W., Marshall D., Gress J., Steinberg S. M., Pizzo P. A. Gram-positive infections and the use of vancomycin in 550 episodes of fever and neutropenia. Ann Intern Med. 1988 Jan;108(1):30–35. doi: 10.7326/0003-4819-108-1-30. [DOI] [PubMed] [Google Scholar]
  31. Rubin M., Hathorn J. W., Pizzo P. A. Controversies in the management of febrile neutropenic cancer patients. Cancer Invest. 1988;6(2):167–184. doi: 10.3109/07357908809077045. [DOI] [PubMed] [Google Scholar]
  32. Rubin M., Pizzo P. A. Monotherapy for empirical management of febrile neutropenic patients. NCI Monogr. 1990;(9):111–116. [PubMed] [Google Scholar]
  33. Schiffer C. A., Wade J. C. Supportive care: issues in the use of blood products and treatment of infection. Semin Oncol. 1987 Dec;14(4):454–467. [PubMed] [Google Scholar]
  34. Viscoli C. Aspects of infections in children with cancer. Recent Results Cancer Res. 1988;108:71–81. doi: 10.1007/978-3-642-82932-1_10. [DOI] [PubMed] [Google Scholar]
  35. Wade J. C. Antibiotic therapy for the febrile granulocytopenic cancer patient: combination therapy vs. monotherapy. Rev Infect Dis. 1989 Nov-Dec;11 (Suppl 7):S1572–S1581. doi: 10.1093/clinids/11.supplement_7.s1572. [DOI] [PubMed] [Google Scholar]
  36. Wade J. C. Management of infection in patients with acute leukemia. Hematol Oncol Clin North Am. 1993 Feb;7(1):293–315. [PubMed] [Google Scholar]
  37. Weeks J. C., Tierney M. R., Weinstein M. C. Cost effectiveness of prophylactic intravenous immune globulin in chronic lymphocytic leukemia. N Engl J Med. 1991 Jul 11;325(2):81–86. doi: 10.1056/NEJM199107113250202. [DOI] [PubMed] [Google Scholar]
  38. Winston D. J., Ho W. G., Champlin R. E. Current approaches to management of infections in bone marrow transplants. Eur J Cancer Clin Oncol. 1989;25 (Suppl 2):S25–S35. [PubMed] [Google Scholar]
  39. Winston D. J., Ho W. G., Gale R. P. Therapeutic granulocyte transfusions for documented infections. A controlled trial in ninety-five infectious granulocytopenic episodes. Ann Intern Med. 1982 Oct;97(4):509–515. doi: 10.7326/0003-4819-97-4-509. [DOI] [PubMed] [Google Scholar]
  40. Wright D. G. Symposium on infectious complications of neoplastic disease (Part II). Leukocyte transfusions: thinking twice. Am J Med. 1984 Apr;76(4):637–644. doi: 10.1016/0002-9343(84)90288-2. [DOI] [PubMed] [Google Scholar]
  41. Ziegler E. J., Fisher C. J., Jr, Sprung C. L., Straube R. C., Sadoff J. C., Foulke G. E., Wortel C. H., Fink M. P., Dellinger R. P., Teng N. N. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. N Engl J Med. 1991 Feb 14;324(7):429–436. doi: 10.1056/NEJM199102143240701. [DOI] [PubMed] [Google Scholar]

Articles from Journal of the National Medical Association are provided here courtesy of National Medical Association

RESOURCES